Safety concerns about intravenous iron therapy in patients with chronic kidney disease

Anaemia in chronic kidney disease (CKD) is managed primarily with erythropoiesis-stimulating agents (ESAs) and iron therapy. Following concerns around ESA therapy, intravenous (IV) iron is being administered more and more worldwide. However, it is still unclear whether this approach is safe at very...

Descripción completa

Detalles Bibliográficos
Autores principales: Del Vecchio, Lucia, Longhi, Selena, Locatelli, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Chronic Kidney Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4792617/
https://www.ncbi.nlm.nih.gov/pubmed/26985378
http://dx.doi.org/10.1093/ckj/sfv142

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4792617/
https://www.ncbi.nlm.nih.gov/pubmed/26985378
http://dx.doi.org/10.1093/ckj/sfv142

Ejemplares similares